For certain Bayer investors, the entry of a new CEO this summer could mean another shot at breaking up the German conglomerate. And for now, Roche veteran Bill Anderson, poised to take the throne from outgoing chief Werner Baumann in June, is keeping an “open mind.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,